Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 2;26(1):153.
doi: 10.1186/s10194-025-02086-0.

Prevalence, characteristics and management of migraine patients with triptan failure in primary care: the EMR France-Mig study

M Lanteri-Minet  1   2 , C Casarotto  3 , O Bretin  3 , C Collin  3 , M Gugenheim  4 , V Raclot  5 , A Cases  6 , P A Squara  6 , W Aissani  6 , A Saighi  6 , H Lefebvre  6
Affiliations

Prevalence, characteristics and management of migraine patients with triptan failure in primary care: the EMR France-Mig study

M Lanteri-Minet et al. J Headache Pain. .

Abstract

Background: The most used treatments for migraine attacks are triptans, yet a considerable proportion of the population develops treatment failure over time due to ineffectiveness, side effects, and/or contraindications. The aim of the France-Mig study was to quantify the population with triptan failure due to ineligibility or resistance, in the primary care setting, and describe their therapeutic management.

Methods: The France-Mig study was a retrospective analysis of a cohort of patients suffering from migraine in 2022 identified using data from the IQVIA electronic medical records (EMR). Patients were identified using either a migraine diagnosis (ICD-10 G43) or a prescription for migraine-specific drugs. Triptan failure was defined as patients with triptan ineligibility (having a contraindication listed in the summary of product characteristics of triptan or aged over 65 years old) or triptan resistance (unsuccessful intake of two different triptans, following the 2022 European Headache Federation consensus definition).

Results: A total of 16,888 adult patients with migraine diagnosis or migraine-specific treatment prescribed in 2022 and with at least 5 years of look back period were included (after extrapolation, it was estimated that 1,440,169 adults consulted a general practitioner in primary care for migraine in 2022 in metropolitan France, which corresponds to 2.78% of the French population). Among the 16,888 patients fulfilling inclusion criteria, 4,509 (26.7%) were identified as having triptan failure, including 4,024 (23.8%) ineligible patients (1,364 [8.1%] with cardiovascular contraindications for triptans, 700 [4.1%] with non-cardiovascular contraindications, 2,055 [12.2%] with age superior or equal to 65 years) and 604 (3.6%) with triptan resistance. A total of 1,384 (53.9%) patients with ineligibility were prescribed a triptan (after their ineligibility). Among patients with triptan resistance, 273 (45.2%) were prescribed at least 3 different triptan molecules and 41 (6.8%) were prescribed at least 4 different triptan molecules.

Conclusions: Triptans failed in more than a quarter of patients. The high proportion of patients treated with triptan despite contraindication showed a substantial unmet therapeutic need, warranting further research and tailored approaches to improve patient outcomes.

Keywords: Contraindication; Electronic medical record; Migraine; Resistance; Triptan.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Patients are individually informed before data collection by the practitioner that information from their medical files may be used for scientific purposes in an anonymous manner and in compliance with medical secrecy. Patients are informed in advance to allow them, if necessary, to object to the processing of their data even before they are collected by IQVIA. In addition, measures will be taken to make information publicly available regarding the implementation of these treatments. These measures will be visible on the IQVIA France website in a specific personal data section (link to the IQVIA website) and include: a general information notice (link to the General Information Notice) applicable to EMR data and an information notice specific to the study. Consent for publication: Not applicable. Competing interests: EC, OB and CC declare to have no competing interest.AC, PAS, WA, AS and HL are employees of Pfizer France.ML-M reports personal fee for advisory boards, speaker panels or investigation studies from Allergan/Abbvie, Amgen, Astellas, ATI, BMS, Boehringer, Boston Scientific, CoLucid, Convergence, Eli Lilly, GlaxoSmithKline, Grunenthal, Eli Lilly, IPSEN, Lundbeck, Medtronic, MSD, Novartis, Orion Pharma, PerFood, Pfizer, ReckittBenckiser, Saint-Jude, Salvia BioElectronics, Sanofi-Aventis, Teva, UCB, UPSA and Zambon.MG has received speaker/advisory board honoraria from Sanofi-Genzyme, Alexion, Pfizer and Biogen. VR has received speaker/advisory board honoraria from Lundbeck and Pfizer.

Figures

Fig. 1
Fig. 1
Flow chart of selection of adult patients with migraine diagnosis and triptan failure in 2022
Fig. 2
Fig. 2
Extrapolation of the number of patients with migraine in France in 2022
Fig. 3
Fig. 3
Use of triptan in the France-Mig population
See this image and copyright information in PMC

References

    1. GBD 2016 Headache Collaborators (2018) Global, regional, and National burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol Nov 17(11):954–976 - PMC - PubMed
    1. Lantéri-Minet M (2008) The role of general practitioners in migraine management. Cephalalgia Int J Headache Sept 28(Suppl 2):1–8 - PubMed
    1. Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis - PubMed. [cité 6 déc 2024]. Disponible sur: https://pubmed.ncbi.nlm.nih.gov/39293828/ - PMC - PubMed
    1. Moisset X, Demarquay G, de Gaalon S, Roos C, Donnet A, Giraud P et al (2024) Migraine treatment: position paper of the French headache society. Rev Neurol (Paris) Déc 180(10):1087–1099 - PubMed
    1. Lipton RB, Blumenfeld A, Jensen CM, Croop R, Thiry A, L’Italien G et al (2023) Efficacy of Rimegepant for the acute treatment of migraine based on Triptan treatment experience: pooled results from three phase 3 randomized clinical trials. Cephalalgia Int J Headache Févr 43(2):3331024221141686 - PubMed